7th International Meeting
STEROIDS AND NERVOUS SYSTEM
Torino - February 16th - 20th 2013
After a very successful series of meetings (the last was in February 2011), we are delighted to invite you to the 7th International meeting on Steroids and Nervous System, which will once again be held in Torino, between 16-20 February, 2013.
As during the previous meetings, we will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, aging, synaptic connectivity, psychiatric disorders.
We will have 3 keynote lectures, 7 half day symposia, one round table and interactive poster discussions during the coffee and lunch sessions.
- Neurosteroids and GABAa receptor
- Neuroendocrine disruption
- Steroids and hippocampal plasticity
- Estrogens and rapid regulation of behavior
- Genomic and non-genomic effects
- Neuroactive steroids and psychiatric disorders
- Estrogen-regulated synaptic connectivity
- Allopregnanolone and other neurosteroids
For each symposium 4 speaker will present general overviews as well as novel work undertaken by leading laboratories in the field. A few additional short communications (selected by the Organizing Committee) will complete the symposia. As in previous editions, posters' discussion will be the place to discuss emerging trends and new developments of the field.
We are looking forward to your participation.
Roberto C. Melcangi and GianCarlo Panzica
Since 2001, this meeting represented an important event for basic and clinical researchers working on this emerging scientific topic. We will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, the vitamin D, neurodegenerative and psychiatric disorders, and the interference among endocrine disruptors and steroid signaling.
L’inibizione della proteina JNK rallenta la progressione della malattia che colpisce i motoneuroni ed è la prima causa genetica di morte nell’infanzia. Lo dimostra uno studio pubblicato su Frontiers in Molecular Neuroscience dal nostro gruppo di ricerca guidato da Alessandro Vercelli, in collaborazione con l’Istituto Mario Negri di Milano. Chiarire i meccanismi molecolari alla base della SMA può aprire la strada allo sviluppo di nuove terapie.